BTIG Research Lowers Integra LifeSciences (NASDAQ:IART) to Neutral

Integra LifeSciences (NASDAQ:IART) was downgraded by BTIG Research from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, The Fly reports.

Separately, Raymond James reiterated a “hold” rating on shares of Integra LifeSciences in a report on Thursday, June 24th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $73.20.

IART stock opened at $69.95 on Wednesday. The company has a fifty day moving average price of $70.93 and a 200 day moving average price of $70.20. Integra LifeSciences has a 12 month low of $42.12 and a 12 month high of $77.40. The company has a market cap of $5.92 billion, a price-to-earnings ratio of 29.03, a price-to-earnings-growth ratio of 1.57 and a beta of 1.24. The company has a debt-to-equity ratio of 0.95, a current ratio of 3.24 and a quick ratio of 2.22.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, July 27th. The life sciences company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.66 by $0.13. Integra LifeSciences had a net margin of 13.62% and a return on equity of 17.64%. The firm had revenue of $389.99 million during the quarter, compared to the consensus estimate of $376.11 million. As a group, analysts anticipate that Integra LifeSciences will post 3.02 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Integra LifeSciences by 0.7% during the 2nd quarter. Vanguard Group Inc. now owns 6,651,498 shares of the life sciences company’s stock worth $453,899,000 after purchasing an additional 44,050 shares during the last quarter. Champlain Investment Partners LLC boosted its stake in shares of Integra LifeSciences by 1.1% during the 1st quarter. Champlain Investment Partners LLC now owns 6,529,175 shares of the life sciences company’s stock worth $451,101,000 after purchasing an additional 70,710 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Integra LifeSciences by 0.8% during the 1st quarter. Janus Henderson Group PLC now owns 4,657,163 shares of the life sciences company’s stock worth $321,763,000 after purchasing an additional 35,000 shares during the last quarter. Cooke & Bieler LP boosted its stake in shares of Integra LifeSciences by 1.9% during the 2nd quarter. Cooke & Bieler LP now owns 2,750,361 shares of the life sciences company’s stock worth $187,685,000 after purchasing an additional 50,912 shares during the last quarter. Finally, Eaton Vance Management boosted its stake in shares of Integra LifeSciences by 9.9% during the 1st quarter. Eaton Vance Management now owns 2,732,554 shares of the life sciences company’s stock worth $188,792,000 after purchasing an additional 245,121 shares during the last quarter. 87.67% of the stock is currently owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

Further Reading: What is the Nikkei 225 index?    

The Fly logo

Analyst Recommendations for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.